

# A Retrospective Study of Pancreatic Lipomatosis and Its Association with Diabetes Mellitus in General Population in North India

Rajesh Sharma<sup>1</sup>, Manjit Arora<sup>1</sup>, Puneet Gupta<sup>1,\*</sup>, Manik Mahajan<sup>2</sup>, Rattan Paul<sup>1</sup>, Poonam Sharma<sup>3</sup>

<sup>1</sup>Department of Radio-diagnosis and Imaging, ASCOMS Hospital, Jammu University, Jammu, J&K, India

<sup>2</sup>Department of Radio-diagnosis and Imaging, PGIMS, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India

<sup>3</sup>Department of Pathology, GMC Hospital, Jammu University, Jammu, J&K, India

**Abstract** Background/ Introduction: Fatty replacement is a common condition involving the pancreas. Small focal fatty deposits in pancreas are relatively insignificant; however, excessive fat deposition has a pathologic significance and is commonly associated with marked reduction in exocrine function of pancreas. A few studies have investigated the relationship between pancreatic lipomatosis and diabetes mellitus but no such study has been carried out in India according to best of our knowledge. So the objective of this study was to evaluate the incidence of pancreatic lipomatosis in north India and to determine its association with diabetes mellitus. Material and Methods: Multi-Detector Computed Tomography (MDCT) scans of 270 patients who underwent abdominal examination during a period of 2 years at a tertiary care centre in north-west India were retrospectively reviewed. Pancreatic lipomatosis was evaluated in all the patients and their association with diabetes mellitus was analyzed. Results: Among 270 patients, 155 were males & 115 were females. Pancreatic lipomatosis was seen in 8 patients (2.96% cases), even type in 2 and uneven type in 6 cases. In 4 out of 6 (66.7%) patients, the uneven fatty infiltration was of type 1 while in 2 out of 6 (33.3%) patients, type 2 pancreatic lipomatosis was seen. Diabetes mellitus was seen in 14 patients out of 270. Pancreatic lipomatosis was seen in 6 out of 14 diabetic patients (42.8%). Significant correlation was established between pancreatic lipomatosis and diabetes mellitus ( $p < 0.0001$ ). Conclusion: Pancreatic lipomatosis is often an asymptomatic and incidental finding in MDCT seen in 2.96 % cases and significant correlation exists between pancreatic lipomatosis and diabetes mellitus.

**Keywords** Computed tomography, Diabetes mellitus, Pancreas, Lipomatosis

## 1. Introduction

The pancreas is an exocrine and endocrine organ approximately 15-20 cm long that is related to the stomach, duodenum, colon, and spleen. Fatty degeneration of the pancreas is common with aging; the entire pancreas may be replaced by fat, and the patient may have no clinical symptoms. Fatty replacement of exocrine pancreas, also known as fatty infiltration, lipomatosis, adipose atrophy, or lipomatous pseudohypertrophy is a well-documented benign entity of speculative origin [1]. The exact etiopathogenesis behind fatty replacement is not known; however, several predisposing factors have been suggested. These include obesity, diabetes mellitus, chronic pancreatitis, hereditary pancreatitis, pancreatic duct obstruction by calculus or tumor, and cystic fibrosis [2].

Fatty replacement may be focal or diffuse. Focal fatty replacement is the commonest degenerative lesion of pancreas and has no major clinical significance. Total fat replacement is a rare condition and is associated with pancreatic enzyme deficiency and malabsorption. Following are few subtypes:

- Even pancreatic lipomatosis
- Uneven pancreatic lipomatosis

There are four different types of uneven pancreatic lipomatosis. Type 1a (35% of cases) is characterized by replacement of the head with sparing of the uncinate process and peribiliary region; type 1b (36%), by replacement of the head, neck, and body, with sparing of the uncinate process and peribiliary region; type 2a (12%), by replacement of the head, including the uncinate process, and sparing of the peribiliary region; and type 2b (18%), by total replacement of the pancreas with sparing of the peribiliary region [3].

Progressive B-cell dysfunction, in the context of insulin resistance, is a hallmark of type 2 diabetes [4]. Glucose toxicity, ensuing from diabetes related hyperglycemia, has been regarded as a contributor to B-cell damage [5]. In

\* Corresponding author:

puneetgupta619@yahoo.com (Puneet Gupta)

Published online at <http://journal.sapub.org/cmd>

Copyright © 2015 Scientific & Academic Publishing. All Rights Reserved

contrast, chronic exposure of the pancreatic islets to non esterified fatty acids (NEFAs) is considered as a potential primary cause of B-cell dysfunction [6]. In obese individuals, increased lipolysis contributes to high levels of circulating NEFAs, whereas liver insulin resistance leads to elevated hepatic output of triglyceride rich particles [7]. When NEFA supply exceeds utilization, non adipose tissues, including the pancreatic islets, start accumulating triglycerides [6], which is aggravated by the simultaneous presence of hyperglycemia [5, 8, 9]. Experimental and autopsy data indicate that fatty infiltration of the pancreas may contribute to a decrease in B-cell mass and function

Few studies have demonstrated the relationship between pancreatic lipomatosis and diabetes mellitus in the literature. However no such study has been carried out from north India according to our knowledge. The aim of this study is to determine the occurrence of pancreatic lipomatosis in patients with and without diabetes mellitus.

## 2. Material and Methods

This retrospective study was carried out at a tertiary care centre in north-west India from January 2013 to December 2014. All patients who underwent MDCT for any abdominal pathology during this period were included. Exclusion criteria included excess alcohol intake (>20 units/week), history of hepatitis and/or pancreatitis, recent (>3 months) changes in weight (>5%), and history or current use of glucocorticosteroids and thiazolidinediones. The scans were performed using GE Health Care (Bright Speed Elite 16) computed tomography (CT) system which is modified third generation machine. The CT examinations of patients were performed in a craniocaudal direction. Detector collimation settings of  $16 \times 0.75$  were used with 1.25 mm slice thickness. The data were reconstructed at 0.75-mm slice thickness for multiplanar reformation imaging. A local ethics committee had approved the protocol. Two radiologists independent of each other reviewed retrospectively all the CT scans. All the images were reviewed on a PACS using the continuous axial and coronal reformatted images. The decisions about the CT findings were reached by consensus. Pancreatic lipomatosis was defined as a region of fat attenuation (-50 to 150 HU) on non contrast and post contrast CT. Medical records were reviewed to determine clinical findings, presence of obesity (defined as body mass index of greater than 30), diabetes mellitus, and coexistent diseases and laboratory findings of serum amylase, lipase, and total cholesterol levels.

## 3. Results

A total of 270 patients were included in the study. The age of patients varied from 15 years to 75 years. The majority of the patients (31.5 %) belonged to 6th decade (Table 1). Out of 270 patients, 155 (57.4%) were males and 115 (42.6 %) were females with a male to female ratio of 1.35.

2.96 % (8 out of 270) patients had pancreatic lipomatosis on MDCT. Majority of cases with pancreatic lipomatosis (37.5 %) were seen in 6th decade (Table 2). Out of these 8 patients, 5 (62.5%) were males and 3 (37.5%) were females.

Even pancreatic lipomatosis was seen in 2 cases while uneven type was seen in 6 cases. Out of 6 cases with uneven pancreatic lipomatosis, 4 (66.7%) were of type 1 while 2 (33.3%) were type 2 uneven pancreatic lipomatosis (Table 3).

Diabetes mellitus was seen in 14 patients (5.1%), among which pancreatic lipomatosis was found in 6 cases (42.8%). Only 2 cases of pancreatic lipomatosis were seen in patients without diabetes mellitus. Significant correlation ( $p < .0001$ ) was noted between presence of diabetes mellitus and pancreatic lipomatosis.

**Table 1.** Age & Sex Distribution of Patients

Age groups	No. of males	No. of females	Total
11-20	5	3	8
21-30	11	8	19
31-40	23	19	42
41-50	35	28	63
51-60	48	37	85
61-70	25	16	41
>70	8	4	12
Total	155	115	270

**Table 2.** Age & Sex Distribution of Patients with Pancreatic Lipomatosis

Age groups	No. of males	No. of females	Total
11-20	-	-	-
21-30	-	1	1
31-40	-	-	-
41-50	1	-	1
51-60	2	1	3
61-70	1	1	2
>70	1	-	1
Total	5	3	8

**Table 3.** Distribution of Pancreatic Lipomatosis according to Type

Pancreatic lipomatosis	Even Type	Uneven Type	
		Type 1	Type 2
No. of patients	2	4	2

**Table 4.** Correlation between pancreatic lipomatosis and Diabetes mellitus

	Diabetes Mellitus Present	Diabetes Mellitus Absent	P value<0.0001
Pancreatic Lipomatosis present	6	2	
Pancreatic Lipomatosis absent	8	254	

## 4. Discussion

The accumulation of fat in the pancreatic gland has been referred to using various synonyms, such as pancreatic lipomatosis, fatty replacement, fatty infiltration, fatty pancreas, lipomatous pseudohypertrophy, non-alcoholic fatty pancreatic disease and pancreatic steatosis [10]. Pancreatic lipomatosis is becoming an increasing problem worldwide due to the increasing incidence of obesity and diabetes mellitus. Fatty infiltration of the pancreas has been also reported in advanced cases of cystic fibrosis, Shwachman syndrome and Johanson-Blizzard syndrome.

Fatty replacement may be focal or diffuse. Focal fatty replacement is the commonest degenerative lesion of pancreas and has no major clinical significance. Total fat replacement is a rare condition and is associated with pancreatic enzyme deficiency and malabsorption. Fatty replacement may be uniform or unevenly distributed in the pancreas.


Lee JS et al [11] used ultrasonography to evaluate the fat content of the pancreas. They used the increase echogenicity of the pancreatic body over kidney echogenicity as the index of a fatty pancreas, and they found that a fatty pancreas is related only to the metabolic syndrome. However the role of ultrasound in the diagnosis of pancreatic lipomatosis is very limited because the overlying bowel gas causes obscuration of the pancreas and the fatty infiltration results in increased echogenicity of the pancreatic tissue making its differentiation difficult from normal retroperitoneal fat.

Cross-sectional imaging, namely, CT has an important role in the evaluation of pancreatic disease. CT is particularly useful in detecting pancreatic duct obstruction by the calculus or tumor. Fatty infiltration of pancreas is seen on CT evidenced as pancreatic parenchymal soft tissue intermixed with fat. Associated atrophy is also seen in aged individual.


Matsumoto S et al [3] reviewed CT scans of 80 cases with uneven fatty replacement. Uneven fatty replacement of the pancreas was classified into two types. In type 1, the posterior aspect of the head of the pancreas was spared from intense fatty replacement. In type 2, the focal area around the common bile duct (CBD) was spared from fatty replacement. Each type was divided into two subgroups on the basis of whether the body and tail of the pancreas showed intense fatty replacement. Twenty-eight patients (35%) had type 1a replacement, 29 (36%) had type 1b replacement, nine (11%) had type 2a replacement, and 14 (18%) had type 2b replacement. In all patients, the anterior aspect of the head of the pancreas showed distinctly lower attenuation at CT. In our study, majority of the patients (75.0%) were type 1 fatty replacement of head, neck and body (Figure 1a, b) and 25.0% were type 2, fatty replacement of head and uncinate process correlating with the study of Matsumoto S et al [3].

Fat accumulation in the pancreatic islets leads to a decreased insulin secretion and might explain why insulin resistant people cannot encounter the higher demands of insulin and then develop type 2 diabetes mellitus [12-17]. In

addition, a greater proportion of pancreatic fat was associated with increased insulin levels in obese nondiabetic subjects. This may indicate that the toxic effect of pancreatic fat accumulation might require a long time before manifesting in impaired B-cell function and it has been assessed that pancreatic B-cell damage is present for more than a decade before diabetes is diagnosed [18].



**Figure 1.** Axial contrast enhanced CT image showing complete replacement of the pancreatic parenchyma by macroscopic fatty tissue (Even Type of Pancreatic Lipomatosis)



**Figure 2.** Axial contrast enhanced CT image showing replacement of head, neck, body and tail of pancreas by macroscopic fatty tissue with sparing of the uncinate process (Uneven type of Pancreatic Lipomatosis). Note is made of associated emphysematous cholecystitis (black arrow)

In our study, significant association was observed between presence of diabetes mellitus and pancreatic lipomatosis further signifying role of increased fat deposition in pancreas as a precursor and/or etiological factor in diabetes.

Few limitations were encountered in our study. First, it was a retrospective study. Second, chemical shift MRI has recently evolved as a more sensitive technique in diagnosing pancreatic lipomatosis and reducing false positive cases. Third, there was no histopathological confirmation.

Pancreatic lipomatosis is seen in 2.96 % cases in our study and is more common in men than women. Also there exists a significant association between pancreatic lipomatosis and diabetes mellitus indicating that diabetes mellitus may be a

predisposing factor in the development of pancreatic lipomatosis. Thus, adequate control of hyperglycemia and diabetes mellitus must be achieved to prevent development of pancreatic lipomatosis which can lead to malabsorption in severe cases. Furthermore, total fatty replacement of pancreas should always be kept in the mind by the radiologists as it results in malabsorption due to pancreatic exocrine insufficiency.

## REFERENCES

- [1] Patel S, Bellon EM, Haaga J, Park CH. Fat replacement of the exocrine pancreas. *AJR Am J Roentgenol.* 1980 Oct; 135(4):843-5.
- [2] Soyer P, Spelle L, Pelage JP, Dufresne AC, Rondeau Y, Gouhiri M, Scherrer A, Rymer R. Cystic fibrosis in adolescents and adults: fatty replacement of the pancreas-CT evaluation and functional correlation. *Radiology.* 1999 Mar;210(3):611-5.
- [3] Matsumoto S, Mori H, Miyake H, Takaki H, Maeda T, Yamada Y, Oga M. Uneven fatty replacement of the pancreas: evaluation with CT. *Radiology.* 1995 Feb;194(2):453-8.
- [4] Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature.* 2006 Dec 14;444(7121):840-6.
- [5] Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. *Proc Natl Acad Sci U S A.* 1998 Mar 3;95(5):2498-502.
- [6] McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. *Diabetes.* 2002 Jan;51(1):7-18.
- [7] Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. *J Clin Invest.* 2006 Jul;116(7):1802-12.
- [8] Newsholme P, Keane D, Welters HJ, Morgan NG. Life and death decisions of the pancreatic beta-cell: the role of fatty acids. *Clin Sci (Lond).* 2007 Jan;112(1):27-42.
- [9] Kharroubi I, Ladrière L, Cardozo AK, Dogusan Z, Cnop M, Eizirik DL. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. *Endocrinology.* 2004 Nov;145(11):5087-96.
- [10] Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis. *Nat Rev Gastroenterol Hepatol.* 2011 Mar;8(3):169-77.
- [11] Lee JS, Kim SH, Jun DW, Han JH, Jang EC, Park JY, Son BK, Kim SH, Jo YJ, Park YS, Kim YS. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. *World J Gastroenterol.* 2009 Apr 21;15(15):1869-75.
- [12] Ritz-Laser B, Meda P, Constant I, Klages N, Charollais A, Morales A, Magnan C, Ktorza A, Philippe J. Glucose-induced preproinsulin gene expression is inhibited by the free fatty acid palmitate. *Endocrinology.* 1999 Sep;140(9):4005-14.
- [13] Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? *Diabetes.* 2001 Apr;50(4):803-9.
- [14] Bränström R, Leibiger IB, Leibiger B, Corkey BE, Berggren PO, Larsson O. Long chain coenzyme A esters activate the pore-forming subunit (Kir6. 2) of the ATP-regulated potassium channel. *J Biol Chem.* 1998 Nov 20;273(47):31395-400.
- [15] Liang Y, Buettger C, Berner DK, Matschinsky FM. Chronic effect of fatty acids on insulin release is not through the alteration of glucose metabolism in a pancreatic beta-cell line (beta HC9). *Diabetologia.* 1997 Sep;40(9):1018-27.
- [16] El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, Rosenberg L, Prentki M. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. *Endocrinology.* 2003 Sep;144(9):4154-63.
- [17] Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. *Diabetes.* 2003 Mar;52(3):726-33.
- [18] Oakes ND, Bell KS, Furler SM, Camilleri S, Saha AK, Ruderman NB, Chisholm DJ, Kraegen EW. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. *Diabetes.* 1997 Dec;46(12):2022-8.